• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cost-Effectiveness of the New Combination Trifluridine/Tipiracil Plus Bevacizumab for the Third-Line Treatment for Metastatic Colorectal Cancer in Italy.

作者信息

Giuliani Jacopo, Mantoan Beatrice, Mangiola Daniela, Muraro Marco, Napoli Giuseppe, Tommasi Marina, Fiorica Francesco, Mandarà Marta

机构信息

Department of Oncology, Azienda ULSS 9 Scaligera, Legnago (VR), Italy.

Department of Diagnostic Imaging, Azienda ULSS 9 Scaligera, Legnago (VR), Italy.

出版信息

Clin Colorectal Cancer. 2024 Mar;23(1):1-3. doi: 10.1016/j.clcc.2023.10.005. Epub 2023 Oct 14.

DOI:10.1016/j.clcc.2023.10.005
PMID:37932152
Abstract
摘要

相似文献

1
Cost-Effectiveness of the New Combination Trifluridine/Tipiracil Plus Bevacizumab for the Third-Line Treatment for Metastatic Colorectal Cancer in Italy.新型三联疗法曲氟尿苷/替匹嘧啶联合贝伐单抗用于意大利转移性结直肠癌三线治疗的成本效益分析
Clin Colorectal Cancer. 2024 Mar;23(1):1-3. doi: 10.1016/j.clcc.2023.10.005. Epub 2023 Oct 14.
2
Trifluridine/Tipiracil in Combination with Bevacizumab in First-Line for Metastatic Colorectal Cancer: A Way Forward. A Point of View Based on Cost-Effectiveness.曲氟尿苷/替匹嘧啶联合贝伐单抗一线治疗转移性结直肠癌：前进之路。基于成本效益的观点
Clin Colorectal Cancer. 2022 Jun;21(2):e145-e147. doi: 10.1016/j.clcc.2021.11.012. Epub 2021 Dec 5.
3
Trifluridine-tipiracil plus bevacizumab versus trifluridine-tipiracil monotherapy for chemorefractory metastatic colorectal cancer: a systematic review and meta-analysis.替氟尿苷替匹嘧啶联合贝伐珠单抗对比替氟尿苷替匹嘧啶单药治疗化疗耐药转移性结直肠癌的系统评价和荟萃分析。
BMC Cancer. 2024 Jun 3;24(1):674. doi: 10.1186/s12885-024-12447-8.
4
Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer.回顾性队列研究：替氟尿苷/盐酸拓扑替康（TAS-102）联合贝伐珠单抗对比替氟尿苷/盐酸拓扑替康单药治疗转移性结直肠癌。
BMC Cancer. 2019 Dec 27;19(1):1253. doi: 10.1186/s12885-019-6475-6.
5
[Two Cases of Metastatic Colorectal Cancer Treated with TAS-102 plus Bevacizumab].TAS-102联合贝伐单抗治疗转移性结直肠癌2例
Gan To Kagaku Ryoho. 2021 Mar;48(3):419-421.
6
A Systematic Review and Meta-Analysis of Trifluridine/Tipiracil plus Bevacizumab for the Treatment of Metastatic Colorectal Cancer: Evidence from Real-World Series.三氟尿苷/替匹嘧啶联合贝伐珠单抗治疗转移性结直肠癌的系统评价和荟萃分析：来自真实世界系列的证据。
Curr Oncol. 2023 May 24;30(6):5227-5239. doi: 10.3390/curroncol30060397.
7
Trifluridine/Tipiracil Plus Bevacizumab for Vulnerable Patients With Pretreated Metastatic Colorectal Cancer: A Retrospective Study (WJOG14520G).氟尿嘧啶替匹嘧啶+贝伐珠单抗治疗预处理转移性结直肠癌脆弱患者：一项回顾性研究（WJOG14520G）
Oncologist. 2024 Mar 4;29(3):e330-e336. doi: 10.1093/oncolo/oyad296.
8
Cost-effectiveness of Trifluridine/tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales.英国和威尔士既往治疗转移性结直肠癌患者中使用曲氟尿苷替匹嘧啶的成本效果分析。
Clin Colorectal Cancer. 2018 Mar;17(1):e143-e151. doi: 10.1016/j.clcc.2017.09.001. Epub 2017 Sep 28.
9
Phase I study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second-line therapy for patients with metastatic colorectal cancer.TAS-102（替拉鲁肽/曲氟尿苷）联合伊立替康加贝伐珠单抗二线治疗转移性结直肠癌的 I 期研究。
Invest New Drugs. 2024 Aug;42(4):454-461. doi: 10.1007/s10637-024-01443-1. Epub 2024 Jul 11.
10
Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan.替氟尿苷/替匹嘧啶对比纳武利尤单抗治疗日本晚期转移性胃癌的成本效果分析。
Jpn J Clin Oncol. 2021 Aug 30;51(9):1383-1390. doi: 10.1093/jjco/hyab086.

引用本文的文献

1
Efficacy and safety of trifluridine/tipiracil plus bevacizumab across different subgroups of patients with refractory colorectal cancer: a meta-analysis.曲氟尿苷/替匹嘧啶联合贝伐单抗治疗难治性结直肠癌不同亚组患者的疗效与安全性：一项荟萃分析
Ecancermedicalscience. 2024 Jul 10;18:1728. doi: 10.3332/ecancer.2024.1728. eCollection 2024.